Author(s): Lipson EJ
Abstract Share this page
Abstract The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.
This article was published in Oncoimmunology
and referenced in Journal of Cancer Science & Therapy